Charting New Territories in Obesity Management- Traditional Techniques to Tirzepatide

IF 3.7 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Endocrine Practice Pub Date : 2025-01-01 DOI:10.1016/j.eprac.2024.09.004

Areeba Fareed MBBS , Laura Ghanem MBBS , Rayyan Vaid MBBS , Zoha Iftikhar MBBS , Adeel Ur Rehman MBBS , Ayesha Sarwar MBBS , Muhammad Iqbal Asif MBBS

{"title":"Charting New Territories in Obesity Management- Traditional Techniques to Tirzepatide","authors":"Areeba Fareed MBBS , Laura Ghanem MBBS , Rayyan Vaid MBBS , Zoha Iftikhar MBBS , Adeel Ur Rehman MBBS , Ayesha Sarwar MBBS , Muhammad Iqbal Asif MBBS","doi":"10.1016/j.eprac.2024.09.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Obesity, a pervasive global health challenge affecting more than 2 billion people, requires comprehensive interventions. Traditional approaches, including lifestyle modification, and diverse drugs targeting a gastrointestinal hormone, including glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (Liraglutide, Semaglutide, Exenatide, Albiglutide, Dulaglutide, Lixisenatide, Orlistat, Phentermine/Topiramate, Lorcaserin, Sibutramine, and Rimonabant) offer tailored strategies; yet their effectiveness is limited and some drugs were taken off the market. Moreover, various surgical modalities, such as Roux-en-Y Bypass surgery, sleeve gastrectomy, intragastric balloons, biliopancreatic diversion with duodenal switch, laparoscopic adjustable gastric band, and vagal nerve blockade can be considered but are associated with numerous side effects and require careful monitoring. Consequently, there is a pressing need for novel anti-obesity treatments.</div></div><div><h3>Methods</h3><div>This comprehensive review was based on the available data to discuss the traditional pharmaceutical and surgical therapeutical strategies for obesity, going further to discuss tirzepatide's mode of action, its outcomes for obesity, and the associated side effects.</div></div><div><h3>Results</h3><div>In this landscape, tirzepatide, initially designed for type 2 diabetes management, emerges as a potential game-changer. Functioning as a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, it not only addresses control but also introduces a fresh perspective on weight reduction. This review intricately explores tirzepatide's mechanism, dissecting insights from clinical studies and positioning it as a major force in obesity treatment.</div></div><div><h3>Conclusions</h3><div>In the middle of significant shifts in obesity management, tirzepatide presents itself as a promising and cost-effective intervention. Its Food and Drug Administration approval marks a milestone in the realm of obesity therapeutics. Going beyond a recapitulation of findings, the conclusion emphasizes the imperative for ongoing exploration and vigilant safety monitoring in tirzepatide's application.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 1","pages":"Pages 102-113"},"PeriodicalIF":3.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine Practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1530891X24006700","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Obesity, a pervasive global health challenge affecting more than 2 billion people, requires comprehensive interventions. Traditional approaches, including lifestyle modification, and diverse drugs targeting a gastrointestinal hormone, including glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (Liraglutide, Semaglutide, Exenatide, Albiglutide, Dulaglutide, Lixisenatide, Orlistat, Phentermine/Topiramate, Lorcaserin, Sibutramine, and Rimonabant) offer tailored strategies; yet their effectiveness is limited and some drugs were taken off the market. Moreover, various surgical modalities, such as Roux-en-Y Bypass surgery, sleeve gastrectomy, intragastric balloons, biliopancreatic diversion with duodenal switch, laparoscopic adjustable gastric band, and vagal nerve blockade can be considered but are associated with numerous side effects and require careful monitoring. Consequently, there is a pressing need for novel anti-obesity treatments.

Methods

This comprehensive review was based on the available data to discuss the traditional pharmaceutical and surgical therapeutical strategies for obesity, going further to discuss tirzepatide's mode of action, its outcomes for obesity, and the associated side effects.

Results

In this landscape, tirzepatide, initially designed for type 2 diabetes management, emerges as a potential game-changer. Functioning as a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, it not only addresses control but also introduces a fresh perspective on weight reduction. This review intricately explores tirzepatide's mechanism, dissecting insights from clinical studies and positioning it as a major force in obesity treatment.

Conclusions

In the middle of significant shifts in obesity management, tirzepatide presents itself as a promising and cost-effective intervention. Its Food and Drug Administration approval marks a milestone in the realm of obesity therapeutics. Going beyond a recapitulation of findings, the conclusion emphasizes the imperative for ongoing exploration and vigilant safety monitoring in tirzepatide's application.

Abstract Image

查看原文本刊更多论文

开拓肥胖症治疗的新领域--从传统技术到替氮帕肽。

肥胖症是一项普遍存在的全球健康挑战，影响着 20 多亿人，需要采取综合干预措施。传统方法，包括改变生活方式，以及针对胃肠激素的各种药物，包括葡萄糖依赖性胰岛素促多肽（GIP）和胰高血糖素样肽-1（GLP-1）（利拉鲁肽、赛马鲁肽、艾塞那肽、阿尔比格鲁肽、杜拉鲁肽、利西那肽、奥利司他、酚特明/托吡酯、洛卡西林、西布曲明、利莫那班），提供了量身定制的策略；然而，这些药物的疗效有限，有些药物已退出市场。此外，还可以考虑采用各种手术方式，如鲁克斯-Y 旁路手术、袖状胃切除术、胃内气球、十二指肠转换胆胰转流术（BPD/DS）、腹腔镜可调节胃束带（LAGB）和迷走神经阻断术，但这些手术方式都有许多副作用，需要仔细监测。因此，人们迫切需要新型的抗肥胖治疗方法。在这种情况下，最初设计用于治疗 2 型糖尿病（T2D）的替唑帕肽成为了改变游戏规则的潜在药物。作为一种双重 GIP/GLP-1 受体激动剂，它不仅能控制体重，还能为减轻体重带来新的视角。这篇综述深入探讨了替哌肽的作用机制，剖析了临床研究的见解，并将其定位为肥胖症治疗领域的一支重要力量。在肥胖症治疗的重大转变中，替扎帕肽是一种前景广阔、成本效益高的干预药物。美国食品和药物管理局（FDA）对它的批准标志着肥胖症治疗领域的一个里程碑。结论不仅仅是对研究结果的回顾，它还强调了在应用替扎帕肽的过程中不断探索和警惕安全性监测的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Endocrine Practice ENDOCRINOLOGY & METABOLISM-

CiteScore

7.60

自引率

2.40%

发文量

546

审稿时长

41 days

期刊介绍： Endocrine Practice (ISSN: 1530-891X), a peer-reviewed journal published twelve times a year, is the official journal of the American Association of Clinical Endocrinologists (AACE). The primary mission of Endocrine Practice is to enhance the health care of patients with endocrine diseases through continuing education of practicing endocrinologists.